• In June 2026, Abbott’s board declared a quarterly dividend of US$0.63 per share, marking the company’s 410th consecutive quarterly payout since 1924, payable on August 17, 2026 to shareholders of record as of July 15, 2026.
• Around the same time, ALZpath announced it had licensed its proprietary pTau217 antibody to Abbott for use in a blood-based Alzheimer’s diagnostic test on the widely deployed Alinity ci-series systems, highlighting Abbott’s push into earlier neurodegenerative disease detection.
• We’ll now examine how the ALZpath licensing deal for an Alzheimer’s blood test could influence Abbott’s broader investment narrative.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe in its diversified healthcare portfolio, recurring demand from chronic disease care and an emphasis on diagnostics and medical devices. Near term, the key catalyst remains execution in core diagnostics and diabetes devices, while the biggest risk is sustained weakness or pricing pressure in diagnostics, particularly in China. The ALZpath licensing deal is positive for Abbott’s innovation story, but its immediate impact on these nearer term drivers looks limited.

The dividend decision is the most directly relevant announcement here: Abbott’s 410th consecutive quarterly payout of US$0.63 per share underlines a long record of returning cash to shareholders, even as it leans into areas like Alzheimer’s testing. For investors weighing the ALZpath agreement, that combination of ongoing shareholder returns and incremental innovation in diagnostics frames how this news fits alongside existing catalysts in devices and emerging markets.

Yet alongside this, ongoing pricing and policy uncertainty in China’s diagnostics market is something investors should be aware of as...

Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and a $3.2 billion earnings increase from $6.3 billion.

Uncover how Abbott Laboratories' forecasts yield a $116.54 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community see Abbott’s fair value between US$116.54 and US$140.67, highlighting varied expectations. When you set this against ongoing diagnostics headwinds in China, it underlines why exploring several different viewpoints on Abbott’s prospects can be so important.

Explore 6 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 55% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.